Compare CCSI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | MYGN |
|---|---|---|
| Founded | 2021 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.6M | 444.2M |
| IPO Year | 2022 | 1996 |
| Metric | CCSI | MYGN |
|---|---|---|
| Price | $26.45 | $4.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $37.50 | $7.64 |
| AVG Volume (30 Days) | 81.0K | ★ 983.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.35 | N/A |
| Revenue | $349,696,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $3.33 | $6.86 |
| Revenue Next Year | $2.70 | $5.45 |
| P/E Ratio | $6.37 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $19.24 | $3.76 |
| 52 Week High | $31.67 | $8.59 |
| Indicator | CCSI | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 36.06 |
| Support Level | $26.42 | $3.76 |
| Resistance Level | $26.62 | $5.52 |
| Average True Range (ATR) | 1.22 | 0.29 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 39.90 | 25.32 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.